New Developments in Peptide Receptor Radionuclide Therapy

Abstract

Peptide receptor radionuclide therapy (PRRT) is an established treatment for nonoperable or metastatic neuroendocrine neoplasms that highly and frequently express somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a molecular target. The development of imaging companions gave rise to the concept of radiotheranostics, important for in vivo tumor detection, characterization, and staging but also, and more importantly, for individual patient selection and treatment. The success of somatostatin receptor targeting paved the way for the clinical translation of other peptide-based radiopharmaceuticals targeting, for example, the receptors cholecystokinin 2, gastrin-releasing peptide, neurokinin-1, and C-X-C motif chemokine 4. Although historically the Auger emitter 111 In and the high-energy β − emitter 90 Y were used, most PRRT are currently performed with the medium-energy β − emitter 177 Lu, whereas α emitters are increasingly studied in various clinical applications. New Developments in Peptide ReceptorRadionuclide Therapy http://jnm.snmjournals.org/content/60/2/167 This article and updated information are available at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients

“…Neuroendocrine tumours (NETs) frequently overexpress somatostatin receptors, in particular subtype 2 (sst2), on the tumour cell membrane. These somatostatin receptors represent important molecular targets for imaging and therapy, using either radiolabelled or “cold” peptide analogues [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]. Peptide receptor radionuclide therapy (PRRT) with 90 yttrium- or 177 lutetium-labelled somatostatin analogues such as DOTATOC or DOTATATE has proven its safety and efficacy in patients with inoperable/metastatic gastroenteropancreatic NETs [ 2 , 4 , 5 , 7 , 8 ].…”

Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study

“…Third, some recently published important papers might not have gained enough attention from researchers and thus may not be discussed in detail in our study. For example, the review ( Nicolas et al, 2019 ) recommended by a reviewer, which is a review published in 2019, summarized the recent developments (e.g., 213 Bi and 225 Ac) in PRRT. Therefore, there is still a need to observe the latest published achievements.…”

Immunohistochemical expression of chemokine receptor in neuroendocrine neoplasms (CXCR4) of the gastrointestinal tract: a retrospective study of 71 cases

“…This therapy uses cytotoxic radiation against tumoral cells and is usually applied to patients with tumors that express SSTRs. Recently, an attempt has been made to apply this technique against the CXCR4 ligand using 68 Ga-Pentixafor/ 177 Lu/ 90 Y-Pentixather or scandium and terbium radioisotopes [ 22 ].…”